Lumos Pharma, Inc.

LUMO · NASDAQ
Analyze with AI
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Activities
Net Income-$34-$31-$30-$6
Dep. & Amort.$0$0$0$1
Deferred Tax$0$0$0-$10
Stock-Based Comp.$2$2$3$1
Change in WC$1$2-$2-$4
Other Non-Cash-$0-$0$0-$6
Operating Cash Flow-$31-$27-$30-$23
Investing Activities
PP&E Inv.$0-$0-$0-$0
Net Acquisitions$0$0$0$84
Inv. Purchases-$7-$11$0$0
Inv. Sales/Matur.$18$0$0$0
Other Inv. Act.$0-$11$26$33
Investing Cash Flow$11-$11$26$117
Financing Activities
Debt Repay.$0$0$0-$0
Stock Issued$1$0-$0$117
Stock Repurch.-$1-$1-$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$0-$0$0
Financing Cash Flow-$1-$1-$0$0
Forex Effect$0$0$0$0
Net Chg. in Cash-$21-$39-$4$94
Supplemental Information
Beg. Cash$56$95$99$5
End Cash$35$56$95$99
Free Cash Flow-$31-$27-$30-$23
Lumos Pharma, Inc. (LUMO) Financial Statements & Key Stats | AlphaPilot